PRMEPrime Medicine Inc. Common Stock
3.390USD-4.24%Mkt Cap: 614.87M $P/E: —3d ago
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap614.87M $
Enterprise Value593.82M $
Revenue (TTM)4.07M $
Gross Profit-142.13M $
Net Income (TTM)-201.14M $
Revenue/Share0.0240 USD
Last Price3.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees146
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.66
PEG—
EV/EBITDA-3.14
EV/Revenue145.79
P/S144.28
P/B14.40
EPS (TTM)-0.96
EPS (Forward)-0.88
52W Range
2.67017% of range6.940
52W High6.940 USD
52W Low2.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-3750.87%
EBITDA Margin0.00%
Profit Margin-4342.44%
ROE-166.41%
ROA-58.69%
Growth
Revenue Growth3.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.56M $
CapEx (TTM)4.53M $
FCF Margin-1860.55%
FCF Yield-12.32%
Net Debt17.41M $
Net Debt/EBITDA-0.09
Balance Sheet
Debt/Equity0.96
Current Ratio3.06
Quick Ratio3.00
Book Value/Sh0.2250 USD
Cash/Share0.5340 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.295 USD
Upside (mean)+115.2%
Target Range4.250 USD – 11.00 USD
$4.250+115.2% to mean$11.00
# Analysts11
Ownership
Shares Out.181.38M
Float112.25M
Insiders23.66%
Institutions71.11%
Short Interest
Short Ratio9.3d
Short % Float24.67%
Short % Out.19.30%
Shares Short35.00M
Short (prev mo.)34.73M
Technical
SMA 503.269 (+3.7%)
SMA 2003.562 (-4.8%)
Beta2.31
S&P 52W Chg18.16%
Avg Vol (30d)3.03M
Avg Vol (10d)2.61M
Technical Indicators
RSI (14)56.2
MACD0.0185
MACD Signal-0.0352
MACD Hist.+0.0537
BB Upper3.429 USD
BB Middle3.093 USD
BB Lower2.757 USD
BB Width21.76%
ATR (14)0.2309 USD
Vol Ratio (20d)1.37x